|
Dr. Gentile joined Hambrecht & Quist Capital Management in September 2002 as Vice President, Research. His emphasis is on the analysis of private and public companies in the fields of functional genomics and proteomics, as well as cell and gene therapy. He is also an Adjunct Associate Professor of Biotechnology at Brown University. Previously, Dr. Gentile was Vice President, Technology Program Management at Millennium Pharmaceuticals, for which he was responsible for managing all technology platform development programs. Prior to joining Millennium, Dr. Gentile was Vice President of Product Development at Curis, Inc., a biotechnology company developing products in the area of regenerative medicine. He also served as Director and then Vice President, Program Management at Reprogenesis, Inc., and held several scientific and management positions at CytoTherapeutics, Inc. Prior to working in industry, he was a postdoctoral fellow at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He has written more than 120 peer-reviewed publications and is an inventor on 30 U.S. patents in the area of biotechnology. Dr. Gentile received a BE in Chemical Engineering from The Cooper Union and a PhD in Chemical Engineering from MIT. | 